Glucagonostatic Potency of GLP-1 in Patients with Type 2 Diabetes, in Patients with Type 1 Diabetes, and Healthy Control Subjects

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Hyperglucagonemia is a well-known contributor to diabetic hyperglycemia, and glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion. Reduced inhibitory effects of glucose and GLP-1 on glucagon secretion may contribute to the hyperglucagonemia in diabetes and influence the success of GLP-1 receptor agonist therapy. We examined the dose-response relationship for GLP-1 on glucose-induced glucagon suppression in healthy individuals, patients with type 2 and type 1 diabetes. In randomized order, 10 healthy individuals with normal glucose tolerance, 10 patients with type 2 diabetes and 9 C-peptide negative patients with type 1 diabetes, underwent 4 separate stepwise glucose clamps (five 30-minute steps from fasting level to 15 mM plasma glucose) during simultaneous intravenous infusions of saline, 0.2, 0.4 or 0.8 pmol GLP-1/kg/min. In healthy individuals and patients with type 2 diabetes, GLP-1 potentiated the glucagon-suppressive effect of intravenous glucose in a dose-dependent manner. In patients with type 1 diabetes, no significant changes in glucagon secretion were observed during the clamps whether with saline or GLP-1 infusions. In conclusion, the glucagonostatic potency of GLP-1 during a stepwise glucose clamp is preserved in patients with type 2 diabetes, whereas our patients with type 1 diabetes were insensitive to the glucagonostatic effects of both glucose and GLP-1.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind70
Udgave nummer4
Sider (fra-til)1347-1356
ISSN0012-1797
DOI
StatusUdgivet - 2021

ID: 258893204